Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SVON - bought @.90. Tiny market cap with
some big names involved.
Backed by world renowned investors and advisors
Pfizer
Opko Health
Phillip Frost – CEO of OPKO, former Chairman of TEVA
Harlan Waksal – Founder of Imclone, CEO Kadmon
Richard Lerner – Past President Scripps
http://www.seviontherapeutics.com/wp-content/uploads/2015/06/SEVION-BIO-Deck-061215-PDF.pdf
The question was about LPTN. You replied about LPCN.
PKTEF/PKT.v (.49) - bought the stock as it
is down from .63 after announcing a JV in April,
to current levels.
The JV is with PRE LLC , an entity whose members are senior officers of Propark America
and with an affiliate of Och-Ziff Real Estate which is a division of Och-Ziff Capital Management,
a publicly traded company with approx $50 billion of
assets under management.
The parties agreed to acquire and optimize a portfolio of US$500MM in parking lots in the United States.
http://finance.yahoo.com/news/parkit-announces-joint-venture-214429339.html
Recent insider buys by the CEO and others as high as .60:
https://www.canadianinsider.com/company?menu_tickersearch=PKT%20|%20Parkit%20Enterprise
Q1 results:
http://finance.yahoo.com/news/parkit-announces-record-profit-q1-120000339.html
May presentation:
http://www.parkitenterprise.com/investors/PKT-CorpPres-May2015-web.pdf
Generic A.D.H.D. Drug, Not Equivalent to the Brand, Is in Use Anyway
By KATIE THOMAS JUNE 16, 2015
When Dr. Louis Kraus, a chief of child psychiatry at a hospital in Chicago, writes prescriptions for patients who have attention-deficit hyperactivity disorder, he often chooses Concerta, an extended-release form of the drug Ritalin that gives patients relief from their symptoms for as long as 12 hours.
He was unconcerned when, a few years ago, pharmacies began substituting lower-cost generic alternatives for brand-name Concerta — after all, generic drugs are widely seen as effective and account for the overwhelming majority of prescriptions filled nationwide.
His feelings changed last November, however, when the Food and Drug Administration announced that two of the three available Concerta generics, one made by Mallinckrodt Pharmaceuticals and the other by UCB, could no longer be considered the equivalent of the brand and, in most states, could not be automatically substituted by pharmacies for the brand name.
“This is a concoction to justify the giving out of medication at unprecedented and unjustifiable levels,” Keith Conners, a psychologist and early advocate for recognition of A.D.H.D., said of the rising rates of diagnosis of the disorder.
The agency said that although it considered the drugs to be safe, its own lab tests and other analyses suggested that their effectiveness began to wear off much more quickly — after about seven hours. That time frame is important, because the pill can be taken only once a day.
Photo
Dr. Louis Kraus, a psychiatrist, says some insurers ask him to change his prescriptions. Credit Nathan Weber for The New York Times
The agency allowed the companies to continue selling their drugs, but gave them six months to either prove the drugs were equivalent, or remove them from the market.
Seven months later, the deadline has passed and the drugs are still being sold. Major pharmacies like CVS and Rite Aid continue to stock them, and together the drugs have managed to hold on to about 30 percent of the market. (A third product, sold by Actavis, was found to be equivalent to the brand. Johnson & Johnson makes Concerta as well as the Actavis generic.)
“This has gone on for months,” said Dr. Kraus, who is the chief of child psychiatry at Rush University Medical Center. The lack of action by the F.D.A., he said, has undermined his faith in generics. “We’re as much in the black as the patients are. And then we find this out, and it’s really frightening.”
UCB has said it submitted new information last week that will show it is equivalent to Concerta, although it has not shared that information publicly. But Mallinckrodt Pharmaceuticals has taken a different tack: It is challenging the agency’s decision in court. Both companies say they have no plans to withdraw their products.
A spokeswoman for the F.D.A. declined to comment because of the Mallinckrodt lawsuit.
In part, the dispute reflects the controversy around the ability of generic companies to reproduce extended-release drugs, which require more technical expertise to manufacture. The F.D.A. has said it is looking more closely at extended-release generics and has set aside $20 million to test generics for safety and quality. Attention-deficit drugs were among the agency’s initial targets.
When Concerta was approved in 2000, it was welcomed by doctors because it eliminated the need for patients to take Ritalin three times a day. Previous efforts at developing long-acting forms of the drug had not been as successful. With Concerta, parents could give a child a pill before the child left for school, eliminating midday trips to the school nurse’s office for a new dose.
Concerta’s secret was the way that it released the drug: The pill absorbed fluid as it passed through the body, and pumped the active drug out of a laser-cut hole.
Under F.D.A. rules, generic companies do not need to use the same mechanisms to produce copycat versions of long-acting drugs. The manufacturers must instead prove that their products release the drug into the body at the same rate as the brand-name drug. The Mallinckrodt and UCB products use different techniques, which may account for the shorter effectiveness.
When word of the F.D.A.’s November decision spread, many Wall Street analysts expected that sales of the two drugs would plummet or that Mallinckrodt and UCB would follow the path of the drug maker Teva, which in 2012 withdrew its version of an extended-release version of Wellbutrin, an antidepressant, after the F.D.A. made a similar decision about its product. Mallinckrodt’s stock dropped 7 percent at the time, but has since rebounded.
“It’s the first time we’re seeing something exactly like this,” said Ronny Gal, an analyst with Sanford C. Bernstein & Company. “I kind of thought the F.D.A. would tell them to go away. They haven’t.”
Instead, Mallinckrodt went on the offensive. And Actavis, now the only approved substitute for Concerta, raised its prices.
Dr. Kraus, the child psychiatrist, said he still fielded regular calls from pharmacies and some insurers asking him to change his prescriptions so they can dispense the cheaper generics — drugs that he considers inferior. “I’m enraged about it,” Dr. Kraus said.
Representatives for CVS and Rite Aid said they sell all three generic versions and noted that the F.D.A. has said they are safe. A spokesman for CVS, Michael J. DeAngelis, denied that the company was directing pharmacies to ask doctors to switch their prescriptions. He would not comment on suggestions by some that pharmacies and insurers are motivated to sell the cheaper brands because they reap financial benefits from doing so. He said CVS was dispensing more of the Actavis product than the other two versions.
Rite Aid would not comment on its financial arrangements with the generic companies, or on whether its pharmacists were asking doctors to switch prescriptions.
A spokeswoman for Walgreens said the Actavis product had been its preferred generic since 2011, although it continues to stock the other two versions because some doctors write prescriptions for them; more than 99 percent of its extended-release prescriptions were filled with the Actavis product in May.
In November, Actavis held about 50 percent of the market for generic Concerta, according to an analysis Mr. Gal provided. As of May, that share had grown to 70 percent, but the two other products still hold a significant portion of the market.
Mallinckrodt’s chief executive, Mark Trudeau, told investors in May that he expected to keep the product on the market for the “foreseeable future.”
“It’s very puzzling to me,” said Dr. Harry Lever, a cardiologist at the Cleveland Clinic who has become an advocate for improving the quality of generic drugs. “If the F.D.A. rules it’s not the same, how can it be sold? I don’t understand the rationale for that happening.”
Mr. Gal said the agency’s lack of action had created a bizarre secondary market for the drugs.
“From a regulatory standpoint, it’s a really bad idea to create an additional market for a drug that’s not exactly the same, but in the ballpark,” Mr. Gal said. “You’re a regulator. Regulate.”
http://www.nytimes.com/2015/06/17/business/generic-ritalin-drug-not-equivalent-to-the-brand-is-in-use-anyway.html?_r=0
Thanks pmony.
MOC - Good for us. It means that we will probably
have another chance to buy it lower for another round.
Their annual report should also be out soon.
MOC - sold @2.92 for a 45% profit. The PR says that:
>>On June 17, 2015, the Company was notified by the United States Department of Justice that ABM has expressed an intent to file a protest with the Court of Federal Claims challenging the award of the USPS contract to the Company, and seeking an injunction to stop the transition of the USPS contract to the Company. The Company cannot predict the duration or outcome of the dispute, including whether the transition will occur.<<
So more BS ahead.
MOC - Command Security Corporation Notified of the U. S. Postal Service's Decision to Confirm Contract Award
Command Security Corporation
22 minutes ago
GlobeNewswire
HERNDON, Va., June 18, 2015 (GLOBE NEWSWIRE) -- Command Security Corporation (NYSE MKT: MOC) announced today the notification by the U. S. Postal Service (“USPS”) of their decision regarding the previously announced contract award.
On December 31, 2014, Command Security Corporation (“Command Security” or the “Company”) received notification of the award of the USPS contract under Solicitation No. 2B-14-A-0078, valued at approximately $250 million over a ten year term of service. The contract provides for security services at 50 USPS locations in 18 states, Puerto Rico and the District of Columbia, valued at approximately $20 million per year, as well as the operation of the two USPS National Law Enforcement Communication Centers (NLECC) at Dulles International Airport, Virginia and in Ft. Worth, Texas, valued at approximately $5 million per year. The award includes a four year base contract and three two-year options.
On January 29, 2015 the Company announced that the USPS had issued a stay of the transition of the contract awarded to the Company pending the resolution of a dispute over the award of such contract. The contract at issue was disclosed in a press release issued by the Company on January 6, 2015, and in a Form 8-K filed by the Company with the Securities and Exchange Commission on January 12, 2015. On January 27, 2015, the Company was notified by the USPS that ABM Security Services (“ABM”) had lodged a protest with the USPS seeking to overturn the contract that was awarded to the Company.
In a decision dated June 15, 2015, the USPS Supplier Disagreement Resolution Officer found that the December 31, 2014 contract awarded to the Company represented the best value for the USPS. Accordingly, the Supplier Disagreement Resolution Officer denied the disagreement filed by ABM, and lifted the stay on the performance of the December 31, 2014 contract with the Company.
On June 17, 2015, the Company was notified by the United States Department of Justice that ABM has expressed an intent to file a protest with the Court of Federal Claims challenging the award of the USPS contract to the Company, and seeking an injunction to stop the transition of the USPS contract to the Company. The Company cannot predict the duration or outcome of the dispute, including whether the transition will occur.
About Command Security Corporation
Command Security Corporation and its Aviation Safeguards subsidiary provides uniformed security officers, aviation security services and support security services to commercial, financial, industrial, aviation and governmental customers throughout the United States. We safeguard against theft, fraud, fire, intrusion, vandalism and the many other threats that our customers are facing today. By partnering with each customer, we design programs customized to meet their specific security needs and address their particular concerns. We bring years of expertise, including sophisticated systems for hiring, training, supervision and oversight, backed by cutting-edge technology, to every situation that our customers face involving security. Our mission is to enable our customers to operate their businesses without disruption or loss, and to create safe environments for their employees. For more information concerning our company, please refer to our website at www.commandsecurity.com.
Forward-Looking Statements
This announcement by Command Security Corporation (referred to herein as the “Company”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and within the meaning of the Private Securities Litigation Reform Act of 1995 about the Company that are based on management’s assumptions, expectations and projections about the Company. Such forward-looking statements by their nature involve a degree of risk and uncertainty. The Company cautions that actual results of the Company could differ materially from those projected in the forward-looking statements as a result of various factors, including but not limited to the factors described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the Securities and Exchange Commission, and such other risks disclosed from time to time in the Company’s periodic and other reports filed with the Securities and Exchange Commission. You should consider the areas of risk described above in connection with any forward-looking statements that may be made by the Company. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any additional disclosures the Company makes in proxy statements, quarterly reports on Form 10-Q, annual reports on Form 10-K and current reports on Form 8-K filed with the Securities and Exchange Commission, which are publicly available at the Securities and Exchange Commission’s website at www.sec.gov/edgar.shtml.
Contact:
Company Contact:
N. Paul Brost
Command Security Corporation
703-464-4735
FNJN: Transforming to Cybersecurity Startup: Finjan Establishes a New Consulting Business
Zacks Small Cap Research By Zacks Small Cap Research
FNJN: Transforming to Cybersecurity Startup: Finjan Establishes a New Consulting Business
Zacks Small Cap Research 1 hr 48 mins ago
By Lisa Thompson
NASDAQ:FNJN
Until this week, Finjan Holdings (FNJN)- has been a pure play in cyber security IP. Its sole source of revenues has been license agreements with other producers of cybersecurity products that use its behavior based threat detection technologies and infringe on it patents. However, it has already had considerable success with investing as a VC with Jerusalem Venture Partners Cybersecurity Fund VII and just received a cash pay out from its portion of an investment in CyActive, which was bought by PayPal for approximately $60 million. Finjan received a distribution from its JVP investment. This investment will yield a Gain on investment of approximately $826,000 in this June quarter and will appear on the income statement under other income.
To continue this diversification away from just licensing, this week Finjan announced the establishment of a new international consulting operation, “CybeRisk” by hiring two world-class executives based in Tel Aviv. It is in effect acting as a VC by starting up a new business. Heading up the group is Yoram Golandsky, who was General Manager of Cisco's Cyber Security Center of Excellence for the past year. Before that he was the founder and CEO of Security Art Ltd., a leader in providing worldwide cybersecurity and information risk management services for five years. He also was the Head of Information Security at RSA (the Security Division of EMC), and Chief Security Officer at PriceWaterhouseCoopers Israel. COO Eyal Harari, also from Cisco’s Cyber Security Center of Excellence, joins him. He also worked for Security Art and consulting firm that performed red team exercises for clients.
The two started with Finjan on Monday June 15, 2015 and there are plans to add perhaps four or more people by year-end. We expect the company to begin adding revenues to the company in Q4 and operate on a cash flow neutral basis for the year.
The company also announced that its non-compete and confidentiality agreement with its former licensee and acquirer of its hardware business, M86 (who subsequently merged with Trustwave, and more recently into SingTel) has expired. It had restricted Finjan from making cybersecurity products. The company now plans to develop and release new products and is moving into direct to consumer applications. Development will be done entirely by Yeti, a San Francisco-based app developer. This company will create the products Finjan brings to them. The first release is mobile browser for IOS and Android (called “Finjan Mobile Secure Browser”) that will scan a website for security and rate it safe, suspicious or avoid before a user actually lands on a page. This browser can be downloaded for free from the Apple App store and the Google Play Store.
Next Events
The next major event is the start of the trial with Blue Coat on June 20, 2015. A Markman hearing with Proofpoint, on June 24, 2015, and then a Markman hearing with Symantec on June 29, 2015 will follow this. We expect the Blue Coat trial to take about two weeks and then the results of that trial to be issued another two weeks later. This trial should be an important indicator of future prospects for litigation.
The company’s has a market cap of $29 million and approximately $15 million in cash but could be worth considerably more if it is successful in its licensing pursuits. Estimating revenues of $23 million in 2015 and an industry multiple of 3.7 times sales, the company could be worth $115 million by next year if it succeeds in reaching successful licensing arrangements.
http://finance.yahoo.com/news/fnjn-transforming-cybersecurity-startup-finjan-161000804.html
Finjan Launches CybeRisk Security Solutions to Provide Cybersecurity Risk and Security Advisory Services to International Markets
Yoram Golandsky Tapped as CEO of New Israel-Based Company Delivering Innovative Comprehensive Security Solutions From the Server Room to the Board Room
Marketwired Finjan Holdings, Inc.
EAST PALO ALTO, CA--(Marketwired - Jun 15, 2015) - Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity company, today announced the launch of CybeRisk Security Solutions ("CybeRisk") to provide cybersecurity risk advisory services to customers around the world. Yoram Golandsky, who previously led Cisco's Cyber Security Center of Excellence as General Manager, has been named Chief Executive Officer of the new company. CybeRisk will service clients throughout Europe, North America, and other key global markets from its headquarters in Tel Aviv.
"Finjan was founded in Israel and, although we're now a Silicon Valley company, our roots there have always been a significant strength. We're excited to be launching CybeRisk in Tel Aviv, which has become the international ground zero for advancements in cybersecurity," said Phil Hartstein, President and CEO of Finjan. "As one of the world's leading security experts, Yoram is optimally positioned to guide the expansion of Finjan's portfolio of offerings into the international cybersecurity services sector."
Golandsky brings to his role of CEO more than 20 years of experience delivering security technology and advisory services in the financial services, ecommerce, and payment system industries. Prior to joining Cisco, he was founder and CEO of Security Art Ltd., a leader in providing worldwide cybersecurity and information risk management services. His other posts have included Head of Information Security at RSA, the Security Division of EMC; and Chief Security Officer at PriceWaterhouseCoopers Israel.
"I'm excited to be charged with building CybeRisk at a time when cybersecurity threats to major corporations and smaller organizations alike are all too real and the potential consequences severe," said Golandsky. "The team we've brought together has unparalleled expertise in providing tailored guidance on the technology side as well as at the board level."
CybeRisk's management team includes COO Eyal Harari, who also joins from Cisco's Cyber Security Center of Excellence. As Business Operations Manager there, Harari was responsible for the Center's commitments to its clients in regards to project initiation, deliverables, finance, quality, and timeframes, in addition to managing the Center's resources and reporting both internally and externally. Prior to his role at Cisco, Harari was Business Operations Manager of Security Art Ltd., and he has also served as Corporate Strategy Manager at Amdocs Inc. and as an independent consultant.
Finjan's investment in CybeRisk is in line with its strategy of reinvesting proceeds from successful cybersecurity investments, while continuing to support its patent monetization program.
Finjan was founded in 1997 to provide disruptive behavior-based threat detection software known today as malware. The company then went on to deliver software and hardware solutions to small and medium businesses as well as enterprise-class deployments. Today, Finjan licenses its intellectual property portfolio, has an active investment in Jerusalem Venture Partner's Cyber Strategic Partners Fund VII, is developing consumer products targeting mobile security and consumer privacy, and, with the introduction of CybeRisk, now operates a premium services business model.
ABOUT FINJAN
Founded in 1997, Finjan is recognized globally as a cybersecurity pioneer and leader. Finjan's investment in innovation is captured in its patent portfolio, centered around software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan's software detects malicious code and protects end users from identity and data theft, spyware, malware, phishing, trojans, and other online threats. To date, Finjan has successfully licensed its intellectual property to major technology companies for more than $150 million. For more information about Finjan, please visit www.finjan.com.
http://finance.yahoo.com/news/finjan-launches-cyberisk-security-solutions-120000986.html
Matt, unlike many other "patent" companies that
lost markman hearing after another, FNJN proved
that they can win either in court or by settling
out of court.
I am not a legal expert and i have no clue how it
will affect FNJN, but at current market cap, it is
worth the gamble to me. There is a risk here and everyone
should invest what they feel comfortable with or
not invest at all.
If i am not mistaken, their lawyers only get money
if they win (10-20% of what FNJN gets), so they wouldn't
take their cases if they didn't think there is a good
chance of winning.
SCKT(2.08) - i bought this week and might buy
more before Q2 results are out, as long as it stays
around this level.
As in previous times i played it, your posts are very
helpful and helps me time my entries. This last post
by you makes me even more comfortable with my buy.
Thanks Dave.
PESI - Perma-Fix Environmental Services to Present at the Impact Investor Conference
Marketwired Perma-Fix Environmental Services, Inc.
ATLANTA, GA--(Marketwired - June 12, 2015) - Perma-Fix Environmental Services, Inc. (PESI), today announced that Ben Naccarato, CFO of Perma-Fix Environmental Services Inc., will be presenting on Friday, June 19, 2015 at 9:30 a.m. Central Time at the 2015 Impact Investor Conference, hosted by The Brewer Group Companies, GWG Holdings, Inc., and Greentree Financial Group. The conference will be held at the Minneapolis Club in Minneapolis, MN.
The Impact Investor Conference will unite small-cap and middle market companies spanning multiple industries whose products, services and technologies are having a positive impact around the globe. It is a platform for experts and investment banks, hedge funds and private investors to collaborate and take advantage of a diverse environment designed to generate ideas in multiple fields with the goal of making a positive impact on the world.
About The Brewer Group
The Brewer Group, Inc. (TBG) is an industry agnostic holding company with assets ranging numerous sectors. TBG's relationships with key international decision makers spanning government development agencies, financial institutions, multinational corporations, NGOs and numerous leaders in sports and entertainment, place TBG in a unique position to grow its portfolio. TBG takes pride in identifying companies whose goal is to make a social impact on the communities in which they serve. For further information, please visit www.thebrewergroup.com.
About Perma-Fix Environmental Services
Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the Department of Defense ("DOD"), and the commercial nuclear industry. The Company's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.
Please visit us on the World Wide Web at http://www.perma-fix.com.
Contact:
David K. Waldman
US Investor Relations
Crescendo Communications, LLC
(212) 671-1021
Herbert Strauss
European Investor Relations
herbert@eu-ir.com
+43 316 296 316
On June 8, 2015, Finjan Holdings, Inc. (the "Company") received a cash distribution of $825,963 as a portion of a gross entitlement of approximately $1.5 million from its investment in JVP VII Cyber Strategic Partners, L.P. (the "JVP Fund"), an Israel-based venture capital fund. This distribution represents a portion of the gross proceeds allocated to the Company's investment, with the remaining amounts to be retained by the JVP Fund to fund future investment activities and pursuant to an 18-month escrow account.
http://ih.advfn.com/p.php?pid=nmona&article=67246450&symbol=FNJN
The play here, is that you
can buy FNJN near 52wk low while having 2 markman
hearings against multi billion companies (PFPT & SYMC)
and one trial within the next 2 months.
There are no guarantees and like with every stock, there
is a risk, but to date, FNJN has successfully licensed
their intellectual property to major technology
companies for more than $150 million.
Look at this presentation on page 11.
For example, they got $38 million from Secure computing
and $85 million from Mcafee.
http://ir.finjan.com/investor-kit/document/3274/investor-deck
So with a market cap of less than $30 million you get
a company that has the potential to win more money than
its entire market cap through litigation\settlements but also:
Reported approximately $15 million in cash with an additional $3 million to be received from existing license agreements over the next 12 months.
Potential for early returns on its investment in Jerusalem Venture Partners Fund VII, Cyber Strategic Partners, a fund in which the Company holds a minority limited partnership interest.
Entered into a license agreement, subsequent to the first quarter with F-Secure Corporation, which requires F-Secure to pay Finjan $1 million.
Began the development of new mobile security applications to protect consumer data and information.
Establishing a new cybersecurity consulting service business.
It took half an hour to get a fill, but i
finished buying back trading shares @3.54.
Looking at the chart, it might correct further
without news, but i would rather buy now and add
more if it goes lower.
FNJN - Finjan Holdings Provides Litigation Update:
June Markman Hearing Dates Set for Proofpoint and Symantec
Marketwired Finjan Holdings, Inc.
EAST PALO ALTO, CA--(Marketwired - Jun 9, 2015) - Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity company, today released an update on its subsidiary Finjan, Inc.'s lawsuits against Proofpoint, Inc. and Symantec Corporation. Both cases are pending in the Northern District of California and have Markman Hearings scheduled in June. The Markman Hearing in the Proofpoint case is set for June 24 and the Markman Hearing for the Symantec case is set for June 29.
Finjan filed a patent infringement lawsuit against Proofpoint on December 16, 2013 (3:13-cv-05808-HSG (CAND)). The Proofpoint matter is before the Honorable Haywood S. Gilliam of the U.S. District Court for the Northern District of California. Finjan asserts that Proofpoint is infringing eight of its U.S. Patent Nos.: 6,154,844; 7,058,822; 7,613,918; 7,647,633; 7,975,305; 8,079,086; 8,141,154; and 8,225,408, which cover Endpoint and Network Security technologies. The Proofpoint Claim Construction or "Markman" Hearing is set for June 24, 2015, at 10 a.m. (PT).
Separately, Finjan filed a patent infringement lawsuit against Symantec on July 1, 2014 (3:14-cv-02998-HSG (CAND)) which is also before Judge Gilliam. Finjan asserts that Symantec is infringing eight of its US Patent Nos.: 6,154,844; 7,613,926; 7,756,996; 7,757,289; 7,930,299; 8,015,182; 8,141,154; and 8,677,494, which cover Network Security, Search Engine, and Endpoint technologies. The Symantec Markman Hearing is set for June 29, 2015, at 1 p.m. (PT).
The Markman hearing is an important pre-trial event in a patent lawsuit, wherein the Court will interpret certain disputed claim terms (aka claim elements) in the asserted Finjan patent claims, after consideration of the parties' evidence. As previously reported in its suits against Blue Coat Systems and Sophos Ltd., Finjan has received favorable claim constructions in support of their infringement assertions in those matters.
"Consistent with our Best Practices, we will continue to present our patent infringement claims credibly and convincingly to establish their merits for the Court," said Julie Mar-Spinola, Chief IP Officer and VP, Legal Operations. Finjan established a set of Licensing Best Practices in 2014 to outline the principles by which it operates and to call upon the intellectual property industry to adopt practices that foster and support technological advancements, investments in innovation, and job creation.
In addition to its patent infringement suits against Proofpoint, Symantec, Blue Coat Systems, and Sophos, Finjan has also filed patent infringement lawsuits against FireEye, Inc. and Palo Alto Networks, Inc. relating to various patents in the Finjan portfolio. The Company will provide timely updates of important events relating to these matters on an ongoing basis.
ABOUT FINJAN
Founded in 1997, Finjan is recognized globally as a cybersecurity pioneer and leader. Finjan's investment in innovation is captured in its patent portfolio, centered around software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan's software detects malicious code and protects end users from identity and data theft, spyware, malware, phishing, trojans, and other online threats. To date, Finjan has successfully licensed its intellectual property to major technology companies for more than $150 million. For more information about Finjan, please visit www.finjan.com.
http://finance.yahoo.com/news/finjan-holdings-provides-litigation-june-120000255.html
Finjan Holdings Provides Litigation Update: June Markman Hearing Dates Set for Proofpoint and Symantec
Marketwired Finjan Holdings, Inc.
EAST PALO ALTO, CA--(Marketwired - Jun 9, 2015) - Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity company, today released an update on its subsidiary Finjan, Inc.'s lawsuits against Proofpoint, Inc. and Symantec Corporation. Both cases are pending in the Northern District of California and have Markman Hearings scheduled in June. The Markman Hearing in the Proofpoint case is set for June 24 and the Markman Hearing for the Symantec case is set for June 29.
Finjan filed a patent infringement lawsuit against Proofpoint on December 16, 2013 (3:13-cv-05808-HSG (CAND)). The Proofpoint matter is before the Honorable Haywood S. Gilliam of the U.S. District Court for the Northern District of California. Finjan asserts that Proofpoint is infringing eight of its U.S. Patent Nos.: 6,154,844; 7,058,822; 7,613,918; 7,647,633; 7,975,305; 8,079,086; 8,141,154; and 8,225,408, which cover Endpoint and Network Security technologies. The Proofpoint Claim Construction or "Markman" Hearing is set for June 24, 2015, at 10 a.m. (PT).
Separately, Finjan filed a patent infringement lawsuit against Symantec on July 1, 2014 (3:14-cv-02998-HSG (CAND)) which is also before Judge Gilliam. Finjan asserts that Symantec is infringing eight of its US Patent Nos.: 6,154,844; 7,613,926; 7,756,996; 7,757,289; 7,930,299; 8,015,182; 8,141,154; and 8,677,494, which cover Network Security, Search Engine, and Endpoint technologies. The Symantec Markman Hearing is set for June 29, 2015, at 1 p.m. (PT).
The Markman hearing is an important pre-trial event in a patent lawsuit, wherein the Court will interpret certain disputed claim terms (aka claim elements) in the asserted Finjan patent claims, after consideration of the parties' evidence. As previously reported in its suits against Blue Coat Systems and Sophos Ltd., Finjan has received favorable claim constructions in support of their infringement assertions in those matters.
"Consistent with our Best Practices, we will continue to present our patent infringement claims credibly and convincingly to establish their merits for the Court," said Julie Mar-Spinola, Chief IP Officer and VP, Legal Operations. Finjan established a set of Licensing Best Practices in 2014 to outline the principles by which it operates and to call upon the intellectual property industry to adopt practices that foster and support technological advancements, investments in innovation, and job creation.
In addition to its patent infringement suits against Proofpoint, Symantec, Blue Coat Systems, and Sophos, Finjan has also filed patent infringement lawsuits against FireEye, Inc. and Palo Alto Networks, Inc. relating to various patents in the Finjan portfolio. The Company will provide timely updates of important events relating to these matters on an ongoing basis.
ABOUT FINJAN
Founded in 1997, Finjan is recognized globally as a cybersecurity pioneer and leader. Finjan's investment in innovation is captured in its patent portfolio, centered around software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan's software detects malicious code and protects end users from identity and data theft, spyware, malware, phishing, trojans, and other online threats. To date, Finjan has successfully licensed its intellectual property to major technology companies for more than $150 million. For more information about Finjan, please visit www.finjan.com.
http://finance.yahoo.com/news/finjan-holdings-provides-litigation-june-120000255.html
PESI - >>how they are going to raise the $6M-$20M
to file with the FDA<<
$20 million sounds like way too much.
What they need to do is list Perma-Fix Medical
on the NASDAQ while doing a raise of no more than
$10 million. The problem is that Perma-Fix Medical's
volume on Poland is pathetic and the market cap is low.
At such market cap the dilution should be minimal IMO.
Once they list on a major exchange in the US, hopefully,
the market cap should go up to a more reasonable level.
Perma-Fix Medical SA quote:
http://www.gpwinfostrefa.pl/GPWIS2/en/emitents/basicInfo/GUARDIER,PLGURDR00013,1
Perma-Fix Medical Confirms Successful Tests at 4 Curie Level; Achieves Another Major Milestone Towards Scale-Up of Non-Uranium Process to Produce Technetium-99m
New Process Eliminates Proliferation Risk and the Need for Either High or Low Enriched Uranium Targets
Marketwired Perma-Fix Environmental Services, Inc.
ATLANTA,GA--(Marketwired - June 08, 2015) - Perma-Fix Environmental Services, Inc. (PESI), today announced that Perma-Fix Medical SA, a subsidiary of the company, completed another successful scale-up of its process to produce Technetium-99m (Tc-99m) from Molybdenum-99 (Mo-99). The tests confirmed that the Company's proprietary resins could withstand higher levels of radiation, up to 4 curies, while producing clinically useful doses of Tc-99m. These results follow previously announced tests that verified success at the 2 curie level. Perma-Fix Medical plans to conduct additional demonstrations at higher curie levels in the near future, as part of its multi-step validation of its technology.
Perma-Fix Medical's process, now verified at the 4 curie level, has numerous benefits over traditional processes for producing Technetium-99m, the most widely used medical isotope in the world, including:
the new process is cost effective and does not require the use of government-subsidized, weapons-grade materials, including Highly Enriched Uranium (HEU) or Low Enriched Uranium (LEU) targets, which are frequently cited as proliferation risks;
the process eliminates many environmental concerns associated with Mo-99 production, including both HEU and LEU processes, both of which produce large quantities of high level waste containing enriched uranium;
it can be performed in most standard research reactors, which should help solve concerns regarding supply shortages of Tc-99m around the world.
Stephen Belcher, CEO of Perma-Fix Medical, commented, "Achieving these results at the 4 curie level marks a major achievement within the industry. We not only exceed industry requirements in many emerging markets that are in need of a decentralized and stable supply chain, but we are also moving rapidly to demonstrate our superiority over traditional processes in the North American and European markets. Based on these results, we remain convinced that our process has the potential to reshape the global supply chain of Tc-99m in the United States and around the world."
Dr. Louis F. Centofanti, CEO of Perma-Fix Environmental Services and Chairman of Perma-Fix Medical, commented, "Following our recent success at the 2 curie level, we have already attracted significant interest from within the industry -- further validating the significance of our process. Given our latest success at the 4 curie level, and near term plans to scale up even further, we are moving forward aggressively with our plans to formalize additional partnerships, prepare for regulatory submission, and, ultimately, commence commercialization of the process."
Tc-99m allows medical practitioners to image internal body organs and is used in 80-85% of the 25 million diagnostic nuclear medical procedures each year in the U.S. alone. Common procedures include: cardiac imaging; cancer detection bone scans; gastrointestinal issues; and imaging of the brain, kidney, spleen and infections. The radioisotope market in Europe alone is expected to reach $1.6 billion in 2017, up from $1.1 billion in 2012.
Nearly all of the world's supply of Tc-99m comes from the thermal fission of highly enriched uranium (HEU) targets in a small number of highly specialized reactors. The current process is costly and has proven an unreliable source of radioactive material leading to severe worldwide shortages. The scheduled closure of the NRU reactor in 2016 and the OSIRIS reactor in France in 2018 are expected to have a further impact on the manufacturing and supply of these isotopes. The current process also raises serious proliferation concerns related to the threat associated with international production, transportation and/or use of HEU in the production of medical isotopes.
Related Quotes
Perma-Fix's technology has the potential to overcome these issues by using neutron capture to activate natural Molybdenum, a common metal, to produce Mo-99, which decays into Tc-99m. Unlike conventional processes, the Perma-Fix Medical process can be produced locally using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. The new process encompasses the full production cycle, from reactor to final medical supply, and should be easily deployable around the world.
To overcome past issues with neutron activation of Molybdenum, Perma-Fix has developed a specialized resin that is radiation resistant and holds large quantities of Molybdenum, but at the same time releases almost 90% of the Tc-99m as it forms from the decay of Mo-99. The resin, loaded with the activated Mo-99, is placed in a Technetium generator and slowly washed with a saline based solution. The eluent solution containing Tc-99m has been shown to meet targeted USP and EUP standards for Pertechnetate.
About Perma-Fix Environmental Services
Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the Department of Defense ("DOD"), and the commercial nuclear industry. The Company's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.
Please visit us on the World Wide Web at http://www.perma-fix.com.
About Perma-Fix Medical
Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at http://www.medical-isotope.com
http://finance.yahoo.com/news/perma-fix-medical-confirms-successful-113000661.html
PESI - Perma-Fix Medical Confirms Successful Tests at 4 Curie Level; Achieves Another Major Milestone Towards Scale-Up of Non-Uranium Process to Produce Technetium-99m
New Process Eliminates Proliferation Risk and the Need for Either High or Low Enriched Uranium Targets
Marketwired Perma-Fix Environmental Services, Inc.
ATLANTA,GA--(Marketwired - June 08, 2015) - Perma-Fix Environmental Services, Inc. (PESI), today announced that Perma-Fix Medical SA, a subsidiary of the company, completed another successful scale-up of its process to produce Technetium-99m (Tc-99m) from Molybdenum-99 (Mo-99). The tests confirmed that the Company's proprietary resins could withstand higher levels of radiation, up to 4 curies, while producing clinically useful doses of Tc-99m. These results follow previously announced tests that verified success at the 2 curie level. Perma-Fix Medical plans to conduct additional demonstrations at higher curie levels in the near future, as part of its multi-step validation of its technology.
Perma-Fix Medical's process, now verified at the 4 curie level, has numerous benefits over traditional processes for producing Technetium-99m, the most widely used medical isotope in the world, including:
the new process is cost effective and does not require the use of government-subsidized, weapons-grade materials, including Highly Enriched Uranium (HEU) or Low Enriched Uranium (LEU) targets, which are frequently cited as proliferation risks;
the process eliminates many environmental concerns associated with Mo-99 production, including both HEU and LEU processes, both of which produce large quantities of high level waste containing enriched uranium;
it can be performed in most standard research reactors, which should help solve concerns regarding supply shortages of Tc-99m around the world.
Stephen Belcher, CEO of Perma-Fix Medical, commented, "Achieving these results at the 4 curie level marks a major achievement within the industry. We not only exceed industry requirements in many emerging markets that are in need of a decentralized and stable supply chain, but we are also moving rapidly to demonstrate our superiority over traditional processes in the North American and European markets. Based on these results, we remain convinced that our process has the potential to reshape the global supply chain of Tc-99m in the United States and around the world."
Dr. Louis F. Centofanti, CEO of Perma-Fix Environmental Services and Chairman of Perma-Fix Medical, commented, "Following our recent success at the 2 curie level, we have already attracted significant interest from within the industry -- further validating the significance of our process. Given our latest success at the 4 curie level, and near term plans to scale up even further, we are moving forward aggressively with our plans to formalize additional partnerships, prepare for regulatory submission, and, ultimately, commence commercialization of the process."
Tc-99m allows medical practitioners to image internal body organs and is used in 80-85% of the 25 million diagnostic nuclear medical procedures each year in the U.S. alone. Common procedures include: cardiac imaging; cancer detection bone scans; gastrointestinal issues; and imaging of the brain, kidney, spleen and infections. The radioisotope market in Europe alone is expected to reach $1.6 billion in 2017, up from $1.1 billion in 2012.
Nearly all of the world's supply of Tc-99m comes from the thermal fission of highly enriched uranium (HEU) targets in a small number of highly specialized reactors. The current process is costly and has proven an unreliable source of radioactive material leading to severe worldwide shortages. The scheduled closure of the NRU reactor in 2016 and the OSIRIS reactor in France in 2018 are expected to have a further impact on the manufacturing and supply of these isotopes. The current process also raises serious proliferation concerns related to the threat associated with international production, transportation and/or use of HEU in the production of medical isotopes.
Related Quotes
Perma-Fix's technology has the potential to overcome these issues by using neutron capture to activate natural Molybdenum, a common metal, to produce Mo-99, which decays into Tc-99m. Unlike conventional processes, the Perma-Fix Medical process can be produced locally using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. The new process encompasses the full production cycle, from reactor to final medical supply, and should be easily deployable around the world.
To overcome past issues with neutron activation of Molybdenum, Perma-Fix has developed a specialized resin that is radiation resistant and holds large quantities of Molybdenum, but at the same time releases almost 90% of the Tc-99m as it forms from the decay of Mo-99. The resin, loaded with the activated Mo-99, is placed in a Technetium generator and slowly washed with a saline based solution. The eluent solution containing Tc-99m has been shown to meet targeted USP and EUP standards for Pertechnetate.
About Perma-Fix Environmental Services
Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the Department of Defense ("DOD"), and the commercial nuclear industry. The Company's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.
Please visit us on the World Wide Web at http://www.perma-fix.com.
About Perma-Fix Medical
Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at http://www.medical-isotope.com
http://finance.yahoo.com/news/perma-fix-medical-confirms-successful-113000661.html
Sold the trading shares @3.7. 17% in a few
days. rinse and repeat. When it flies, i will
always have my core position but meanehile it
has become a great trading stock.
Usually this is when you want to buy,
when nobody's watching and you can buy
before it gets noticed.
In FNJN's case, you get to buy it near 52wk
low while having 2 markman hearings and one
trial within the next 2 months.
OML.v/olncf - new June presentation:
http://www.omni-lite.com/image/presentation.pdf
FNJN (1.33) - i bought in the last
few days. The stock is near 52wk low with
some potentially lucrative near term catalysts.
http://ir.finjan.com/investor-kit/document/3294/enforcement-schedule
Marcum Investor Presentation:
http://wsw.com/webcast/marcum3/fnjn/index.aspx
Finjan Provides Litigation Update -- Favorable Rulings on Motions for Summary Judgment Entered in Blue Coat Case
http://finance.yahoo.com/news/finjan-provides-litigation-favorable-rulings-120100160.html
FNJN - i bought around 1.32 in the last
few days. The stock is near 52wk low with
some potentially lucrative near term catalysts.
http://ir.finjan.com/investor-kit/document/3294/enforcement-schedule
CPXX - sold @2.63 for a 28% profit. Stock is
up 16% on more than 3 times average volume
after one hour of trading.
I used to be very frustrated with IPCI until
i decided that the best way to play it is to
have core position and trading position.
Since then, it's like an ATM and i really like the
stock now :) Sold trading shares
yesterday @3.7 and bought back now @3.17
This is unbelievable that those FDA idiots
haven't approved anything other than Focalin by now.
OML.v - Omni-Lite Signs Long-Term Letter of Agreement with Current Automotive Customer
PR Newswire Omni-Lite Industries Canada Inc.
May 25, 2015 12:37 PM EDT
Revenues increase by 25% in first four months of 2015
Production output increases 37% in first four months
Omni-Lite receives large forging system back from Japan
US$577,413 in new contracts announced
CERRITOS, CA, May 26, 2015 /CNW/ - Omni-Lite Industries Canada Inc. (the "Company") (OML.V) is pleased to note that it has recently signed a long-term Letter of Agreement with an existing automotive customer. It is the intention of both parties to complete a Strategic Alliance Agreement detailing this arrangement by June 20, 2015. This program could ultimately include the development of several products and could include new intellectual property that would be shared by the parties. As such, the agreement will extend over the life of the patent(s), which would be approximately 20 years. "This program represents a significant development for Omni-Lite as it highlights the point that major customers are now willing to develop long-term product development and supply agreements with the Company," stated Allen W. Maxin, president. "Under this agreement the first products will be provided by August this year. The production ramp up is anticipated to continue through 2015 and 2016."
The Company is also pleased to note that it has received new contracts in the amount of US$577,413. Of these orders, approximately 46% are in the Aerospace division, 39% are in the Specialty Automotive division and 15% are in the Sports and Recreation division.
The Company's revenues in the first four months of fiscal 2015 were approximately US$2,140,000. This represents an increase of approximately 25% over revenues in the first four months of 2014. Over the same period, the Company's production output increased by approximately 37%. Of particular significance, military sales grew from a very small base to become 29% of sales in the four month period.
"The Company has recently received the large forging system that was sent back to Japan in November last year," stated Michael Walker, VP of R and D. "Quickly putting this machine back in service will be critical to meeting the new demands from both the Aerospace and Automotive Industries. Our production will again be enhanced when we receive the new custom modified, seven station forging system that is arriving in August of this year."
Omni-Lite Industries Canada Inc. is a rapidly growing high technology company that develops and manufactures precision components utilized by Fortune 500 companies including Boeing, Airbus, Bombardier, Embraer, Alcoa, Ford, Borg Warner, Chrysler, the U.S. Military, Nike, and adidas.
And this from last week:
Omni-Lite Industries Announces Additional Normal
Course Issuer Bid
http://finance.yahoo.com/news/omni-lite-industries-announces-additional-131000397.html
IPCI - Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
Intellipharmaceutics International Inc.
1 hour ago
GlobeNewswire
TORONTO, May 21, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA") provided the Company with notification regarding its Investigational New Drug Application ("IND") submission for Rexista(TM) Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets. The notification from the FDA stated that the Company will not be required to conduct Phase III studies if bioequivalence to Oxycontin(TM) is demonstrated.
The Company had earlier announced, on March 30, 2015, that it had submitted an IND to the FDA for Rexista(TM) Oxycodone XR in anticipation of the commencement of Phase III clinical trials. At the same time the Company had also announced that topline data results of three definitive Phase I pharmacokinetic clinical trials (single dose fasting, single dose steady-state fasting, and single dose fed) all met the bioequivalence criteria when compared to the existing branded drug Oxycontin(TM). The Company believes, in light of these prior results, that it will not be required to conduct Phase III studies, although no assurance to that effect can be given.
The Company believes the FDA notification is significant as it provides a basis for an accelerated development plan for its Rexista(TM) Oxycodone XR product candidate, without the need for more costly and time-consuming Phase III studies. The Company intends to file a New Drug Application ("NDA") for Rexista(TM) Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets with the FDA within the next 6 to 12 months, although no assurance to this effect can be given. Further, there can be no assurance that the FDA will ultimately approve the NDA for sale of Rexista(TM) Oxycodone XR in the U.S. market, or that it will ever be successfully commercialized.
"We are thrilled with the FDA's positive acknowledgement, which enables us to accelerate the development and commercialization of our abuse deterrent Rexista(TM) Oxycodone XR product candidate," stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. "The avoidance of a Phase III trial eliminates a significant financial hurdle. More importantly, it shortens the development timeline and potential time to market."
Rexista(TM) Oxycodone XR
Rexista(TM) Oxycodone XR is the Company's non-generic extended release formulation intended for the management of moderate to severe pain when an around-the-clock analgesic is required. The formulation is intended to present a significant barrier to tampering when subjected to various forms of anticipated physical and chemical manipulation commonly used by abusers. It is also designed to prevent dose dumping when inadvertently or intentionally co-administered with alcohol. In addition, when crushed or pulverized and hydrated, the proposed extended release formulation is designed to coagulate instantaneously and entrap the drug in a viscous hydrogel, which is intended to prevent syringing, injecting or snorting.
About Intellipharmaceutics
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix(TM) technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 5, 15 and 30 mg strengths which received final FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications filed with the FDA (and one Abbreviated New Drug Submission filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.
Intellipharmaceutics also has NDA 505(b)(2) product candidates in its development pipeline. These include Rexista(TM) oxycodone XR, an abuse-deterrent oxycodone, based on its proprietary nPODDDS(TM) novel Point Of Divergence Drug Delivery System and PODRAS(TM) Paradoxical OverDose Resistance Activating System, and Regabatin(TM) XR pregabalin extended-release capsules.
http://finance.yahoo.com/news/intellipharmaceutics-intends-accelerate-rexista-tm-120000720.html
AMPG - AmpliTech Group Reports First Quarter Profit
NEW YORK, May 20, 2015 /PRNewswire/ -- AmpliTech Group, Inc. (OTC-QB: AMPG) filed their 10-Q for the first quarter of 2015. CEO Fawad Maqbool stated, "AmpliTech Group has been following a path towards reducing its debt and operating expenses as well as increasing its bookings and revenue. We have taken great strides towards our goals as stated in our previous press releases and I am pleased to report the highlights of those advances below."
Net consolidated profit and EBITDA of $48,000 vs. net loss of $82,000 in 1Q 2014
Increase in revenue by 7% vs. 1Q 2014's revenue
Decrease in Cost of Goods (COGS) by 16%
Increase in gross profit by 34%
Minimal payables and no convertible or long term debt
Reduction of interest expense
Reduction of overall liabilities by 17%
Mr. Maqbool also stated, "It is evident that the company has 'turned the corner' as shown by its overall performance and growth this year. Our bookings have been increasing so we expect that we can sustain this performance with increased profitability for the rest of the year. We further anticipate that our new product development and planned joint ventures will also help to keep us on the path to growth and technical excellence."
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
http://www.prnewswire.com/news-releases/amplitech-group-reports-first-quarter-profit-300086307.html
AmpliTech Group Reports First Quarter Profit
NEW YORK, May 20, 2015 /PRNewswire/ -- AmpliTech Group, Inc. (OTC-QB: AMPG) filed their 10-Q for the first quarter of 2015. CEO Fawad Maqbool stated, "AmpliTech Group has been following a path towards reducing its debt and operating expenses as well as increasing its bookings and revenue. We have taken great strides towards our goals as stated in our previous press releases and I am pleased to report the highlights of those advances below."
Net consolidated profit and EBITDA of $48,000 vs. net loss of $82,000 in 1Q 2014
Increase in revenue by 7% vs. 1Q 2014's revenue
Decrease in Cost of Goods (COGS) by 16%
Increase in gross profit by 34%
Minimal payables and no convertible or long term debt
Reduction of interest expense
Reduction of overall liabilities by 17%
Mr. Maqbool also stated, "It is evident that the company has 'turned the corner' as shown by its overall performance and growth this year. Our bookings have been increasing so we expect that we can sustain this performance with increased profitability for the rest of the year. We further anticipate that our new product development and planned joint ventures will also help to keep us on the path to growth and technical excellence."
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
http://www.prnewswire.com/news-releases/amplitech-group-reports-first-quarter-profit-300086307.html
KINS - A.M. Best Upgrades Ratings of Kingstone Insurance Company and Kingstone Companies Inc.
Business Wire A.M. Best Company, Inc.
OLDWICK, N.J.--(BUSINESS WIRE)--
A.M. Best has upgraded the financial strength rating to B++ (Good) from B+ (Good) and the issuer credit rating (ICR) to “bbb” from “bbb-” of Kingstone Insurance Company (Kingstone) and the ICR to “bb” from “bb-” of the publicly traded holding company of Kingstone, Kingstone Companies, Inc. (KINS). The outlook for all ratings has been revised to stable from positive. Both companies are headquartered in Kingston, NY.
The ratings upgrade reflects Kingstone’s improved risk-adjusted capitalization in recent years and continued favorable operating earnings, which have enabled it to consistently grow its policyholders’ surplus. Kingstone’s risk-adjusted capitalization significantly improved at year-end 2013, driven by a $15.0 million capital contribution from its parent, following an $18.8 million public offering on Dec. 13, 2013. The capital raised in this public offering also enabled management to repay all of its outstanding debt at Kingstone Companies, Inc.
The ratings reflect Kingstone’s solid risk-adjusted capitalization, favorable five-year operating performance and local market knowledge in its predominant operating territory of New York State. The company’s favorable operating performance is reflected in its double-digit five-year pre-tax returns on revenue and equity, generated by positive net underwriting income and supplemented by net investment and other income. Kingstone’s policyholders’ surplus growth has been solid over the past five years, increasing at a double-digit average annual rate. Additionally, the ICR for Kingstone Companies, Inc. acknowledges the standard notching off of the ICR for the operating company.
Partially offsetting Kingstone’s positive rating factors are its dependence on reinsurance and its concentration of risk, primarily in downstate New York, which exposes it to weather-related events, as well as to market, regulatory and judicial issues. Additionally, Kingstone reported substantial growth in net premiums written in 2014 and is projecting substantial growth in 2015, driven by increased retention on its quota share reinsurance contracts and new policy growth. However, Kingstone’s increased capital position and financial flexibility are sufficient to support management’s future growth plans. Furthermore, Kingstone has reported adverse loss reserve development in recent calendar and accident years, driven in part by historical lead paint claims. However, loss reserve development trends have recently shown improvement, driven by management’s strategic initiatives.
While Kingstone’s single-state concentration exposes it to weather-related events, catastrophe exposure is partially mitigated through catastrophe reinsurance, which it purchased at increased limits in recent years, as well as the use of hurricane deductibles, visual risk inspections, distance-from-shore restrictions and surcharges. Additionally, the company has been expanding its operating territory to regions beyond the New York metropolitan area.
The potential for ratings upgrades exists if Kingstone maintains the favorable operating performance that it has demonstrated in recent years and continues to strengthen its risk-adjusted capitalization. There could be negative pressure on Kingstone’s ratings going forward if its favorable operating performance should deteriorate or its risk-adjusted capitalization materially weakens.
The methodology used in determining these ratings is Best’s Credit Rating Methodology, which provides a comprehensive explanation of A.M. Best’s rating process and contains the different rating criteria employed in the rating process. Best’s Credit Rating Methodology can be found at www.ambest.com/ratings/methodology.
Key insurance criteria reports utilized:
Catastrophe Analysis in A.M. Best Ratings
Insurance Holding Company and Debt Ratings
Risk Management and the Rating Process for Insurance Companies
Understanding BCAR for Property/Casualty Insurers
This press release relates to rating(s) that have been published on A.M. Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please visit A.M. Best’s Ratings & Criteria Center.
A.M. Best Company is the world's oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.
Copyright © 2015 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150519006603/en/
Contact:
A.M. Best Company, Inc.
Kenneth Tappen, 908-439-2200, ext. 5248
Senior Financial Analyst
kenneth.tappen@ambest.com
or
Joseph Burtone, 908-439-2200, ext. 5125
Assistant Vice President
joseph.burtone@ambest.com
or
Christopher Sharkey, 908-439-2200, ext. 5159
Manager, Public Relations
christopher.sharkey@ambest.com
or
Jim Peavy, 908-439-2200, ext. 5644
Assistant Vice President, Public Relations
james.peavy@ambest.com
PFIN (8.94) - sold some around here for a 37%
profit. The stock is overbought and stochastics
are in a selling zone.
The results were good and this one is probably
going higher in the long term, but it is always
wise to take profits along the way.
PESI - CFO goes in big with 500 shares @3.6
http://ih.advfn.com/p.php?pid=nmona&article=66926485&symbol=PESI
CPXX - up 17% to 2.4 which is the 200 day MA
on more than average daily volume after one hour
of trading.
PESI - CEO bought 2000 shares @3.69
http://ih.advfn.com/p.php?pid=nmona&article=66879960&symbol=PESI
Net income from operations of $40,703 and they
raised $500,000 @.023 (75,000 Series B stock
convertible into 21,975,000 shares).
KINS - i listened to the CC and thought it
was very good. I added as well.
They applied for licenses in 4 other states.